CD274 and cancer: Cancer immunotherapy, represented by immune checkpoint inhibitors (ICIs) like PD-L1 inhibitors (nivolumab) and anti-angiogenics (bevacizumab), has transformed solid tumor treatment as a new strategy (63, 64).